Novel therapies for multiple myeloma-Reference-Cited by-同舟云学术

Novel therapies for multiple myeloma

Published:2002-12-20 Issue:1 Volume:120 Page:10-17
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Hayashi Toshiaki,Hideshima Teru,Anderson Kenneth C.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2003.03929.x/fullpdf

Reference80 articles.

1. Phase I results from a phase I/II study of arsenic trioxide (As2O3) and ascorbic acid (AA) in relapsed and chemorefractory multiple myeloma;Bahlis;Blood,2001

2. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients;Barlogie;Blood,2001

3. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry;Bleul;Nature,1996

4. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB;Chauhan;Blood,1996

5. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells;Chauhan;Journal of Biological Chemistry,2000

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells;FEBS Journal;2016-01-14

2. New prognostic biomarkers in multiple myeloma;Postępy Higieny i Medycyny Doświadczalnej;2016-01-04

3. A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs;Lab on a Chip;2015

4. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription;Cell Death & Disease;2014-03

5. MicroRNAs in Hematologic Malignancies;Non-coding RNAs and Cancer;2013-10-08